J&J (JNJ) may announce this week that it has agreed to pay up to $2.2B to settle investigations into how it marketed its Risperdal antipsychotic treatment and other drugs, and claims it paid kickbacks to Omnicare (OCR), Bloomberg reports. The company will make a misdemeanor plea, with the deal including a criminal penalty of as much as $600M. [View news story]
J&J (JNJ) may announce this week that it has agreed to pay up to $2.2B to settle investigations into how it marketed its Risperdal antipsychotic treatment and other drugs, and claims it paid kickbacks to Omnicare (OCR), Bloomberg reports. The company will make a misdemeanor plea, with the deal including a criminal penalty of as much as $600M. [View news story]